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Distinction between pleural mesothelioma and 
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asbestos sprayer 
P. J. RYAN, J. L. OATES, J. CROCKER AND D. E. STABLEFORTH 
Departments of Respiratory Medicine and Histopathology, Birmingham Heartlands Hospital, 
Birmingham, U.K. 
Asbestos exposure may cause asbestosis, pleural plaques and benign pleural disease, and may pre-dispose 
to malignant mesothelioma and other neoplasms. The occurrence to two primary tumours in the same 
patient is rare, and the appearance of a pleural mesothelioma and another lung tumour is exceptional. 
The present case report describes a patient who, by standard immunohistochemistry, was thought to 
have mesothelioma at pleuro-pneumonectomy, and adenocarcinoma in the other lung at post-mortem 5 
months later. Subsequent investigation using the MOC31 antibody demonstrated a single pathology of 
adenocarcinoma of the lung. The additional use of this antibody has important histopathogical and legal 
implications. 
RESPIR. MED. (1997) 91, 57-60 
Case Report 
A 59-year-old man presented with a 3-week 
history of increasing dyspnoea, non-productive 
cough and weight loss. He had smoked 20 
cigarettes day - ’ until 12 yr previously. He had 
worked as a coach-builder for 30 yr and, for the 
first 10 yr of this period, had been involved in 
spraying asbestos fibre onto the inside of the 
coach-work as a fire retardant. He was found 
to have a pleural effusion, and histology of a 
pleural biopsy was consistent with malignant 
mesothelioma. Bronchoscopy was normal, 
thoracic computed tomographic (CT) scan 
revealed extensive pleural thickening, and a 
bone scan demonstrated several metastases. He 
underwent palliative left pleuro-pneumonectomy 
with extrapleural dissection of the presumed 
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mesothelioma. He remained well for a few 
months but then declined rapidly and died 5 
months post-operatively. At post-mortem 
examination, there were bilateral pleural plaques 
and enlarged lymph nodes at the lung hila and 
in the porta-hepatis. In the remaining right 
lung, there was a palpable malignant tumour, 
histologically an adenocarcinoma, and splenic 
metastases were shown. 
Pathology 
The initial pleural biopsy and the excised left 
lung and pleura both showed histological fea- 
tures of a malignant tumour arising from the 
pleura [Plate l(a)]. At autopsy, however, the 
tumour found in the left side of the chest was too 
advanced to determine whether it was originat- 
ing from pleura or lung, but this and the tumour 
in the right lung were both found to be adeno- 
carcinoma [Plate 1 (c)l. Histological review and 
further immunohistochemistry of the initial 
biopsy and resected left lung confirmed that the 
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PLATE 1. (a) Surgical specimen with Haematoxylin 
and Eosin (H+E) stain demonstrating a tubulo- 
papillary pattern. (b) The same tumour with no 
reaction when stained for CD15 activity (Leu Ml). 
(c) At autopsy, even allowing for autolysis, the 
tumour has a very different appearance with H + E 
stain. It is very poorly differentiated with none of 
the architecture in (a). (d) The same tumour as (c) 
stained for CD15 and reacting strongly. 
TABLE 1. 
neoplasm was a tubulo-papillary mesothelioma 
[Plate l(b)]; however, at the time of death, the 
tumour in the right lung and in the left side of 
the chest both had the features of a poorly- 
differentiated adenocarcinoma [Plate l(d)]. The 
latter had probably spread across from the right 
side before death. The results of histochemistry 
are summarized in Table 1. Several months 
afterwards, all the histological specimens were 
re-examined using the MOC31 antibody and all 
were positive [Plate 21. Immunostaining the 
MOC31 was repeated with the same result. 
Discussion 
Multiple primary malignant tumours are uncom- 
mon and, although asbestos exposure is associ- 
ated with the development of several different 
types of tumour, the development of more than 
one histologically distinct carcinoma is rarely 
reported. Selikoff et al. found two or more 
primary tumours in 48 (2%) of 2271 deaths of 
American insulation workers, although it is 
uncertain what proportion of these carcinomas 
were directly related to their asbestos exposure 
(1). The following combinations of tumour in 
asbestos workers have been recorded: pleural 
mesothelioma and renal adenocarcinoma (2), 
peritoneal mesothelioma and laryngeal squa- 
mous cell carcinoma (3); lung carcinoma - 
squamous and adenocarcinoma (4); squamous 
cell carcinoma of lung and adenocarcinoma of 
colon (4); and stomach and colon adenocarci- 
noma (5). There has only been one report of 
Right lung: Left lung: 





Leu Ml positive 
EMA positive 
HAM 56 positive 
Original diagnosis = adenocarcinoma 
MOC3 1 positive 





Leu Ml negative 
EMA negative 
Original diagnosis=mesothelioma 
MOC3 1 positive 
Final diagnosis = adenocarcinoma 
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PLATE 2. Surgical specimen demonstrating strong 
reaction with MOC3 1 immunohistochemistry. 
malignant pleural mesothelioma and adenocar- 
cinema of the lung. In that case, as in the present 
case, the tumours were differentiated by a panel 
of antibodies (CEA, B72.3, LEU, Ml), although 
MOC31 was not available (6). In the present 
case, there was no evidence of the right lung 
carcinoma on the pre-operative thoracic CT 
scan. Prior to MOC31 immunohistochemistry, it 
appeared that a mesothelioma was the primary 
diagnosis, and on this basis, the widow of the 
deceased instigated legal proceedings to claim 
compensation. The action had to be discontin- 
ued when adenocarcinoma was found to be the 
sole cause of the left-sided pleural tumour and 
the right-sided pulmonary mass. 
Although both epithelioid pleural meso- 
thelioma and adenocarcinoma of the lung have 
a poor outcome, their histological differentia- 
tion is vital as misdiagnosis is likely to affect 
treatment, prognosis and the result of claims 
for compensation. The distinction between 
these two tumours may be relatively straight- 
forward on clinical and histological grounds, 
but in a small number of cases, immunohisto- 
chemical staining is required to determine the 
origin of poorly differentiated tumours. A large 
number of markers that are preferentially 
expressed in adenocarcinoma, compared to 
mesothelioma, are now available. No single 
marker can distinguish between the two 
pathologies. It has been demonstrated that reac- 
tivity to at least two of the three antibodies LEU 
Ml, CEA and B72.3 is present in all lung 
adenocarcinomas (7). In a similar study by 
Brown et al., the best two markers were found 
to be CEA and B72.3 (both positive: 100% 
specific and 88% sensitive for adenocarcinoma; 
both negative 99% specific and 97% sensitive for 
mesothelioma) (8). That work supported the 
original diagnosis of two pathologies in this 
case (Table 1). MOC31 is a new reagent which 
recognizes a transmembrane glycoprotein 
present on most types of epithelial cell, includ- 
ing adenocarcinoma. It does not recognize 
normal or malignant mesothelial cells, and it 
has proved highly sensitive in differentiating 
adenocarcinoma from mesothelioma or reactive 
mesothelial cells in pleural or ascites cytological 
specimens (9). In a recent study from the present 
authors’ laboratory using MOC3 1 immuno- 
histochemistry, 42 of 43 mesotheliomas were 
negative (the one exception probably a ‘pseudo- 
mesotheliomatous’ adenocarcinoma secondary 
to treatment for childhood lymphoma), and 43 
of 44 adenocarcinomas were positive (the one 
exception being of indeterminate origin) (10). 
Further unpublished work from the present 
authors’ laboratory has shown the value of 
MOC31 in diagnosing adenocarcinoma in cases 
where Leu Ml was negative. Although the 
possibility that MOC 3 1 immunohistochemistry 
was erroneous in this case should be considered, 
pleural biopsy and surgical specimen were both 
positive and a single pathology is clinically more 
plausible. 
It is still not understood how asbestos fibres 
cause malignancy, and it has been suggested that 
the rarity of simultaneous pleural mesothelioma 
and pulmonary adenocarcinoma is because 
different patho-physiological mechanisms are 
involved. This idea may be supported by the 
fact that carcinoma of the lung is more common 
in smokers with asbestosis. However, meso- 
thelioma is not more common amongst smokers, 
and seems to be caused by asbestos exposure 
rather than asbestosis. 
MOC31 appears to be a valuable addition to 
the panel of antibodies required to distinguish 
between some cases of mesothelioma and 
adenocarcinoma. In the case presented, it has 
played a pivotal role in reaching a diagnosis, 
and has important implications in claims for 
compensation for mesothelioma. 
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